Valuation: Colinz Laboratories Limited

Market Cap 174M 1.86M 1.7M 1.57M 1.42M 2.66M 2.79M 18.97M 7.53M 93.93M 6.98M 6.84M 298M P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 92.43M 990K 902K 835K 755K 1.42M 1.48M 10.09M 4M 49.94M 3.71M 3.64M 158M EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.84%
Yield 2025 *
-
Yield 2026 -
08-20 Annjana Dugar, Likhitta Dugar and Antariksh Dugar completed the acquisition of an additional 0.000238% stake in Colinz Laboratories Limited for INR 324. CI
07-30 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-18 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million. CI
06-18 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-17 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/07/25 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/05/25 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
1 day-4.35%
1 week-8.33%
Current month-4.69%
1 month+1.37%
3 months-15.03%
6 months+57.11%
Current year+23.07%
1 week 65.5
Extreme 65.5
69.5
1 month 59
Extreme 59
72.5
Current year 39.31
Extreme 39.31
87.91
1 year 36.58
Extreme 36.58
87.91
3 years 36
Extreme 36
88.7
5 years 18.25
Extreme 18.25
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 74 26/11/1990
Director/Board Member 34 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%-8.33%+53.27%+63.61% 1.86M
-2.29%-5.34%+28.73%+128.34% 1,204B
-2.04%-5.78%+31.91%+78.34% 643B
-0.86%-3.71%+21.74%+105.02% 501B
+0.24%-1.36%+28.03%+68.33% 378B
-3.61%-9.62%+39.73%+30.53% 327B
+0.68%-4.59%+27.37%+51.76% 285B
+0.83%-4.22%-1.89%+32.52% 270B
-1.14%-6.05%+28.16%+65.35% 237B
-1.45%-0.85%+30.03%+120.72% 207B
Average -1.40%-4.10%+28.71%+74.45% 405B
Weighted average by Cap. -1.42%-4.71%+27.09%+88.16%

Financials

2025 2026
Net sales 65.28M 699K 637K 589K 533K 1M 1.05M 7.13M 2.83M 35.27M 2.62M 2.57M 112M 61.36M 657K 599K 554K 501K 940K 984K 6.7M 2.66M 33.16M 2.46M 2.41M 105M
Net income 4.97M 53.17K 48.45K 44.85K 40.56K 76.1K 79.65K 542K 215K 2.68M 199K 195K 8.5M 5.14M 55.09K 50.19K 46.46K 42.03K 78.84K 82.52K 562K 223K 2.78M 207K 202K 8.81M
Net Debt -49.09M -526K -479K -443K -401K -752K -787K -5.36M -2.13M -26.53M -1.97M -1.93M -84.03M -81.39M -871K -794K -735K -665K -1.25M -1.31M -8.88M -3.52M -43.98M -3.27M -3.2M -139M
Projected Income Statement - Annual - Colinz Laboratories Limited
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
20/11/26 ₹66.00 -4.35% 30
19/11/26 ₹69.00 +5.34% 36
18/11/26 ₹65.50 -2.96% 4
17/11/26 ₹67.50 0.00% 465
16/11/26 ₹67.50 -6.25% 67
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock